Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review
Federica Miglietta(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Fabio Puglisi(University of Udine), Daniele Generali(University of Trieste), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alberto Zambelli, Grazia Arpino(University of Naples Federico II), PierFranco Conte(University of Padua), Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Alessandra Fabi(Agostino Gemelli University Polyclinic), Giampaolo Bianchini(Vita-Salute San Raffaele University), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Maria Vittoria Dieci(Istituto Oncologico Veneto), Giuseppe Curigliano(European Institute of Oncology), Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Saverio Cinieri(Ospedale A. Perrino)
Cited by 13
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k